A B S T R A C T To investigate the basis for a clinically important digitalis-quinidine interaction that is characterized by increases in serum digoxin concentrations when quinidine is administered to digoxin-treated patients, we have studied in vitro the interaction of quinidine with the digoxin receptor. Evidence has been obtained that quinidine is capable of decreasing the affinity for digoxin of cardiac glycoside receptor sites on purified Na,K-ATPase and on intact human erythrocyte membranes. As others have shown, quinidine is capable of inhibiting Na,K-ATPase activity, and evidence has been obtained in the current study that, while quinidine can reduce the affinity of the enzyme for digoxin, it is also capable of acting together with digoxin in inhibiting enzyme activity to a degree greater than the inhibitory effect of digoxin alone. The concentrations of digoxin and quinidine used in this study were considerably greater than their therapeutic serum concentrations. Nevertheless, these observations are consistent with the hypothesis that the increases in serum digoxin concentrations and the decreases in volumes of digoxin distribution observed clinically when quinidine is administered to digoxintreated patients may reflect, at least in part, a decrease in the affinity of tissue receptors for digoxin. The possibility must also be considered that enhanced cardiac effects of digoxin may occur clinically as the result of an augmentation, by quinidine, of digoxin effects, which more than compensates for the modest reduction in digoxin binding.
INTRODUCTION
The cinchona alkaloid quinidine is used in the treatment of certain cardiac arrhythmias, notably atrial fibrillation, multiple premature ventricular depolarizations and ventricular tachycardia. Quinidine is frequently administered to patients who are also being treated with digitalis glycosides. Recently, Ejvinsson (1), Leahey et al. (2) , and others (3) (4) (5) have reported that serum concentrations of the digitalis glycoside digoxin almost invariably rise when quinidine is administered to digoxin-treated patients. Leahey et al. suggested that the observed increases in serum digoxin levels might result from the displacement of digoxin from tissue binding sites (2) . Several subsequent studies have suggested that the volume of distribution of digoxin in man (6) (7) (8) and in the dog (9) is decreased during quinidine administration, a finding consistent with the hypothesis of Leahey et al.; however, there has been considerable interindividual variation (8) and, in one study, no change in the volume of distribution was observed (10) . A decrease in renal clearance of digoxin has also been noted (5) (6) (7) (8) (10) (11) (12) (13) (14) (15) , but the relationship of this observation to the increase in serum digoxin is not clear because rises in serum digoxin levels may occur without additional digoxin administration following the institution of quinidine therapy (2, 13) and because the prolongation of the t112 of digoxin elimination observed during quinidine administration (7, 8, 10) has not always been striking (6, 8, 10) .
Several experimental and clinical observations have suggested that interactions between digitalis and quinidine are accompanied by an augmented effect of one or both of these drugs. The addition of quinidine to cultured beating embryonic heart cells together with digoxin resulted in a significant increase in the proportion of arrhythmic cells over that observed with either drug alone (16) . Kwit and Gold (17) have reported that ventricular tachyeardia was induced in digitoxin-treated dogs by doses of quinidine that did not produce this effect without digitalis. It has also been noted that quinidine, in otherwise nontoxic doses, may cause lethal rhythm disturbances in patients (18, 19) and in experimental animals (20) with digitalis intoxication. Finally, it would appear that the incidence of adverse reactions to digitalis is greater in patients receiving quinidine than in patients not receiving this drug (21) and, conversely, that adverse reactions to quinidine are more common in digitalistreated patients than in patients who are not receiving cardiac glycoside therapy (22) .
The basis for these effects of the two drugs has never been firmly established, but several in vitro studies suggest that cardiac glycosides and cinchona alkaloids may interact at a glycoside receptor site at the cellular level. Quinidine, like digitalis glycosides, is capable of inhibiting Na,K-ATPase activity (23) (24) (25) (26) and dihydroquinidine, an active quinidine derivative, binds to the Na,K-ATPase of dog heart (26) . It has also been reported that another cinchona alkaloid, quinine, decreases the initial rate of uptake of the cardiac glycoside ouabain by isolated rat hepatocytes (27) .
These observations have suggested the possibility that the administration of quinidine to patients receiving digitalis may result in decreased binding of digitalis to tissue receptors but that, despite such decreased digitalis binding, certain effects of digitalis at the cellular level are augmented or potentiated by the action of quinidine on these receptors. We have carried out experiments that provide evidence that quinidine is capable of decreasing the affinity of purified sheep kidney Na,K-ATPase and of human erythrocyte membrane receptors for digoxin and that, under certain conditions, quinidine may augment the action of digoxin on Na,K-ATPase. The present report describes these experiments and discusses their possible clinical implications. Measurement of Na,K-ATPase activity. Na,K-ATPase activity was measured by a spectrophotometric coupled enzyme assay (30) in a medium containing 30 mM histidine, 2.5 mM Na2ATP (P-L Biochemicals, Inc., Milwaukee, Wis.), 5.0 mM MgCl2, 10 mM KCI, 95 mM NaCl, 1.0 mM EGTATris, 0.36 mM NADH, 2 mM phosphoenol pyruvate, and 10 ,ul pyruvate kinase/lactate dehydrogenase (Sigma Chemical Co.), pH 7.2. Na,K-ATPase (1.2 ,ug/ml) and quinidine and/or digoxin were incubated in the reaction mixture, without ATP, for 10 min at 30°C and then the reaction was started by adding ATP. The reaction was allowed to proceed until a stable rate was obtained (4-5 min) and then the rate was determined over a subsequent 4-min period.
METHODS
[3H]Digoxin binding to Na,K-ATPase. [3H]digoxin was diluted with nonradioactive digoxin to specific activities of 1,000, 125, or 100 mCi/mmol. The digoxin binding was carried out at 30°C, essentially as described by Wallick and Schwartz (31) using five different standard binding conditions: (a) Mg = 2.5 mM MgCl2; (b) MgATP = 2.5 mM MgCl2 and 2.5 mM Tris-ATP; (c) MgP1 = 2.5 mM MgCl2, and 2.5 mM Tris-phosphate; (d) NaMgATP = 100 mM NaCl, 2.5 mM MgCl2, and 2.5 mM Tris-ATP; (e) NaKMgATP = 100 mM NaCl, 1 mM KCI, 2.5 mM MgCl2, and 2.5 mM Tris-ATP. The medium also contained 50 mM Tris-Cl, pH 7. (35) .
RESULTS
Effects of digoxin and quinidine on Na,K-ATPase activity. The effects of varying concentrations of digoxin and quinidine on the activity of purified Na,-K-ATPase are shown in Fig. 1 . Analysis of the doseresponse curve by Eq. 2 (35) yielded an I50 value, or concentration of digoxin required to produce 50% inhibition, of 1.2 ,uM, with n, the number of calculated interacting binding sites, equal to 1. This I50 value is similar to that reported by Caldwell and Nash (36) for swine brain Na,K-ATPase, 1.6 uM. Quinidine was found to be an effective inhibitor of Na,K-ATPase activity, but its I5o value of 92 ,uM is -80 times higher than that of digoxin, while its n value equaled 2. Quinidine was also found to affect the dose response of the enzyme to digoxin. A noninhibitory concentration of quinidine (10 ,uM) appeared to cause a slight reduction in the effectiveness of lower (< 1 ,uM) concentrations of digoxin. Inhibitory levels of quinidine increased the extent of inhibition beyond that of digoxin alone, but the inhibitory effect appeared to be less than additive. If the assumption is made that digoxin and quinidine are acting independently at separate sites, the predicted inhibition that would occur in the presence of both compounds can be calculated using the following equation: fraction Table I gives the values for the actual observed inhibition at different quinidine and digoxin concentrations and the predicted, or calculated values. The experimental data corresponded well with the calculated values. The largest deviations occurred at noninhibitory levels of quinidine. These data are consistent with the concept that digoxin and quinidine act independently on Na,K-ATPase activity.
Effect of quinidine on digoxin binding to Na,KATPase. The effect of quinidine on [3H]digoxin binding to the enzyme was determined under different binding conditions, each of which alters the affinity of Effect of Quinidine on the Digoxin Receptor (Table II) and at the lower concentrations of digoxin, the experiments depicted in Fig. 2 are not at equilibrium. The data therefore were not evaluated by Scatchard analysis (37) . The data of Fig. 2 digoxin. These data suggest that under some conditions the effect of quinidine is time dependent. Effects of quinidine on the rate of digoxin binding to Na,K-ATPase. If quinidine is altering the KD Of digoxin for Na,K-ATPase, it could do so by altering the association rate constant, the dissociation rate constant, or both. In the presence of Mg (Fig. 3A) and MgATP (Table II) , the rate of binding was reduced by -25%. At this concentration of digoxin (1 ,uM) , no effect on the rate of association could be detected in the presence of MgPi, NaMgATP, or NaKMgATP (Table II) . To determine if quinidine was affecting the affinity of the enzyme for magnesium or sodium, binding was carried out at suboptimal concentrations of these ions. Lowering the concentration of magnesium from 2.5 to 0.25 mM or sodium from 100 to 15 mM caused approximately a 50% reduction in rate in the presence or absence of quinidine (Table II) , suggesting that quinidine has a direct effect on the intrinsic rate constant rather than on the binding of these ions. Although, in the presence of NaMgATP, we were unable to detect a change in the rate of binding at a digoxin concentration of 1 ,uM, we did detect a reduction in the rate at a lower concentration (25 nM) of digoxin (Fig. 3B) . Fig. 4 shows that, in the presence of Mg Effect ofquinidine on rate ofdissociation ofdigoxin from Na,K-ATPase. The effect of quinidine on the rate of dissociation of enzyme-bound digoxin was tested by binding [3H]digoxin (1 ,uM) to Na,K-ATPase for 30 min and then adding an excess of unlabeled ouabain (1 mM) to "chase" the labeled compound. The decrease in bound [3H]digoxin over several hours was observed in the presence and absence of added quinidine (0.2 mM). Fig. 5 shows that the rates of dissociation (Mg only conditions, t1/2 6.0 h and NaKMg-ATP conditions, t1/2 -9.5 h) were not significantly influenced by quinidine. In these experiments, Mg, The effects of quinidine on the rate of digoxin binding to human erythrocytes. The effect of quinidine on digoxin binding to the intact membrane system of human erythrocytes was also investigated. The binding of digoxin to erythrocyte membranes exhibited linear first order rates (Fig. 6 ) and, as shown in Table III Effect of quinidine on the rate of digoxin-induced inhibition of I6Rb+ uptake by erythrocytes. Utilizing the fact that Rb+ has been demonstrated to be taken up by the erythrocyte through the same process that is involved in the active transport ofK+ (38, 39), we used '6Rb+ to study the effect of quinidine upon the action of digoxin on monovalent cation transport in human erythrocytes. Other workers have reported both increases (40, 41) and decreases (42, 43) in 42K+ flux into mammalian cells in the presence of quinidine. As shown in Table IV , quinidine exerted minimal effects on 86Rb+ uptake under the conditions of this study. shown in Fig. 7 , when digoxin was added to erythrocytes that had been incubated in 1 mM quinidine for 2 h, the rate of inhibition was decreased, but quinidine did not alter the final effectiveness of digoxin. The t1/2 values for the inhibition rates are given in Table III and they show that quinidine can cause 186 and 92% increases in the t1/2 values for the rates of inhibition of 19.5 and 95.6 nM digoxin. Less marked increases in t1/2 were observed when 0.1 mM quinidine was used, and no effect was noted in the presence of 10 ,M quinidine. Lack of effect of quinidine on rate of dissociation of digoxin from receptor sites. Although the data obtained using the purified Na,ATPase enzyme did not support the hypothesis that quinidine displaces receptor-bound digoxin, the possibility remained that such displacement could occur with native membrane systems. Therefore, intact erythrocytes were incubated for 2 h with 0.19 ,uM [3H]digoxin, washed, and resuspended in the presence or absence of 1 mM quinidine. In agreement with the experiments with the purified enzyme, quinidine had no effect, although ouabain caused a slight displacement of [3H]digoxin (Table V) . Similarly, the extent to which digoxin inhibited 86Rb+ influx in intact erythrocytes, 4 h after washing them free of unbound digoxin, was not altered by the presence of quinidine (Table V) . DISCUSSION These studies provide evidence that quinidine is capable of decreasing the affinity of receptor sites on purified Na,K-ATPase and on intact erythrocyte membranes for digoxin. Thus, the decreases in volumes of digoxin distribution observed clinically when quinidine is administered to digoxin-treated patients (6) (7) (8) may reflect, at least in part, a decrease in the affinity of tissue receptors for digoxin.
The decrease in affinity of receptors for digoxin noted in this study was slight and no displacement of digoxin could be detected when quinidine was added to Na,K-ATPase preparations or to erythrocyte membranes that had previously been incubated with digoxin. This decrease in the affinity of the receptor for digoxin under nonsaturating conditions should increase serum digoxin concentration as long as quinidine is present. Although the extent to which in vivo bound digoxin levels would decrease is unclear, it should be pointed out that, because <1% of the total body glycoside stores are present in the serum of digoxin-treated patients (44) , a loss of 1% of tissue digoxin stores could result in a twofold increase in serum digoxin concentration, and would approximate the increase frequently noted clinically following quinidine administration (1, 2, 4, 7, 8, (11) (12) (13) (14) (15) . The precision of our experiments on purified Na,K-ATPase (Table V) and in a previous study (32) , is significantly slower than its dissociation rate from receptors in skeletal and cardiac muscle (45) , tissues containing the major pools of glycoside binding sites in man (44) . Therefore, the inability to demonstrate displacement of digoxin from receptor sites in the present study does not constitute incontrovertible evidence against the hypothesis that a displacement of digoxin from tissue receptors by quinidine may contribute to the increased serum digoxin levels observed clinically after quinidine administration.
Although the renal excretion of digoxin in man and in the dog predominantly reflects glomerular filtration of the drug (44, 46) , evidence has been presented that tubular secretion may also play a role in man (47) . Quinidine is capable of decreasing the renal clearance of digoxin (5) (6) (7) (8) (10) (11) (12) (13) (14) (15) , and it has been suggested that quinidine may exert this effect by interfering with the tubular secretion of the cardiac glycoside (6, 7, 10-12, 14, 15 (Table II) while, on the other hand, quinidine had little effect under conditions that favor the phosphorylated form of Na,-K-ATPase (MgP, or NaMgATP). In the absence of direct studies of quinidine binding, our data do not allow us to determine whether Na+ (in the presence of MgATP) or Pi (in the presence of Mg) decreases the affinity of the enzyme for quinidine or directly inhibits the effect of quinidine on the affinity of the enzyme for digoxin. Lowry et al. (25) have reported that inhibitory effects of quinidine on both the Na,KATPase activity and the K+ dependent p-nitrophenylphosphatase activity of rat brain Na,K-ATPase can be reduced in the presence of high K+, thus suggesting that quinidine binding may be ligand dependent. The decreased affinity for digoxin caused by quinidine in the presence of Mg and MgATP also suggests either that binding of quinidine occurs at the digoxin binding site or that quinidine affects the Mg++ binding sites of the enzyme.
Although quinidine at noninhibitory levels (10 ,tM) decreased the action of digoxin, inhibitory concentrations of quinidine augmented the action of digoxin in a manner suggesting independent sites. Moreover, augmentation by quinidine of the effect of digoxin on active monovalent cation transport was not observed in the present study. These findings together with the observations on the importance of ligand conditions for quinidine inhibition of digoxin binding to Na,KATPase suggest that the interaction between digoxin, Na,K-ATPase and quinidine is a complex one. Nevertheless, it is clear from the present study, that despite reducing the affinity of receptors for digoxin, quinidine is capable, at concentrations above 50 ,uM, of augmenting the inhibitory effects of digoxin on Na,-K-ATPase activity in vitro. Caution must be exercised in extrapolating this observation to clinical situations because the concentrations of the two drugs which exerted this combined effect (50 ,uM quinidine and 0.1 uM digoxin) were considerably in excess of their therapeutic serum concentrations in man (5-15 ,uM quinidine and 1-3 nM digoxin) (49, 50) and because in vivo tissue-to-serum drug concentration ratios (44, 51, 52) may differ from the tatios of receptor to medium quinidine and digoxin concentrations under the various conditions used in the current study. The relative ratios of quinidine to digoxin concentrations that were used in these studies are, however, comparable to those observed clinically. We would therefore propose the hypothesis that some of the enhanced cardiac effects of digoxin which have been reported clinically during quinidine treatment (1-3, 13, 18, 53, 54) may result from an augmentation, by quinidine, of digoxin effects that more than compensates for a modest reduction in digoxin binding. In proposing this hypothesis, however, we would not exclude the possibility that impaired digoxin elimination (7, 8, 10) may also play a role in the reported enhancement, by quinidine, of the effects of digoxin.
